|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIAS3 |
Gene summary for PIAS3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIAS3 | Gene ID | 10401 |
| Gene name | protein inhibitor of activated STAT 3 | |
| Gene Alias | ZMIZ5 | |
| Cytomap | 1q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | B3KNI3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10401 | PIAS3 | LZE2T | Human | Esophagus | ESCC | 9.95e-04 | 6.29e-01 | 0.082 |
| 10401 | PIAS3 | LZE4T | Human | Esophagus | ESCC | 3.73e-05 | 1.36e-01 | 0.0811 |
| 10401 | PIAS3 | LZE5T | Human | Esophagus | ESCC | 1.24e-03 | 2.42e-01 | 0.0514 |
| 10401 | PIAS3 | LZE7T | Human | Esophagus | ESCC | 7.80e-07 | 3.95e-01 | 0.0667 |
| 10401 | PIAS3 | LZE8T | Human | Esophagus | ESCC | 2.51e-04 | 8.93e-02 | 0.067 |
| 10401 | PIAS3 | LZE20T | Human | Esophagus | ESCC | 4.20e-03 | 2.45e-01 | 0.0662 |
| 10401 | PIAS3 | LZE22T | Human | Esophagus | ESCC | 3.38e-06 | 6.70e-01 | 0.068 |
| 10401 | PIAS3 | LZE24T | Human | Esophagus | ESCC | 2.41e-19 | 3.89e-01 | 0.0596 |
| 10401 | PIAS3 | LZE21T | Human | Esophagus | ESCC | 2.97e-05 | 3.42e-01 | 0.0655 |
| 10401 | PIAS3 | LZE6T | Human | Esophagus | ESCC | 1.12e-02 | 1.53e-01 | 0.0845 |
| 10401 | PIAS3 | P1T-E | Human | Esophagus | ESCC | 1.28e-06 | 2.81e-01 | 0.0875 |
| 10401 | PIAS3 | P2T-E | Human | Esophagus | ESCC | 2.00e-40 | 6.24e-01 | 0.1177 |
| 10401 | PIAS3 | P4T-E | Human | Esophagus | ESCC | 1.21e-08 | 2.37e-01 | 0.1323 |
| 10401 | PIAS3 | P5T-E | Human | Esophagus | ESCC | 7.25e-04 | 5.37e-02 | 0.1327 |
| 10401 | PIAS3 | P8T-E | Human | Esophagus | ESCC | 1.51e-31 | 4.74e-01 | 0.0889 |
| 10401 | PIAS3 | P9T-E | Human | Esophagus | ESCC | 6.86e-12 | 2.48e-01 | 0.1131 |
| 10401 | PIAS3 | P10T-E | Human | Esophagus | ESCC | 1.22e-42 | 7.03e-01 | 0.116 |
| 10401 | PIAS3 | P11T-E | Human | Esophagus | ESCC | 9.47e-14 | 4.95e-01 | 0.1426 |
| 10401 | PIAS3 | P12T-E | Human | Esophagus | ESCC | 5.43e-38 | 6.29e-01 | 0.1122 |
| 10401 | PIAS3 | P15T-E | Human | Esophagus | ESCC | 5.79e-52 | 1.07e+00 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:190332216 | Esophagus | ESCC | positive regulation of protein modification by small protein conjugation or removal | 99/8552 | 138/18723 | 4.39e-10 | 1.16e-08 | 99 |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:1903321111 | Esophagus | ESCC | negative regulation of protein modification by small protein conjugation or removal | 69/8552 | 95/18723 | 8.54e-08 | 1.44e-06 | 69 |
| GO:001692512 | Esophagus | ESCC | protein sumoylation | 41/8552 | 53/18723 | 2.49e-06 | 2.86e-05 | 41 |
| GO:000257317 | Esophagus | ESCC | myeloid leukocyte differentiation | 128/8552 | 208/18723 | 2.75e-06 | 3.15e-05 | 128 |
| GO:003320914 | Esophagus | ESCC | tumor necrosis factor-mediated signaling pathway | 67/8552 | 99/18723 | 7.87e-06 | 7.72e-05 | 67 |
| GO:003461220 | Esophagus | ESCC | response to tumor necrosis factor | 149/8552 | 253/18723 | 1.47e-05 | 1.33e-04 | 149 |
| GO:007135620 | Esophagus | ESCC | cellular response to tumor necrosis factor | 132/8552 | 229/18723 | 1.69e-04 | 1.11e-03 | 132 |
| GO:1903706110 | Esophagus | ESCC | regulation of hemopoiesis | 201/8552 | 367/18723 | 2.60e-04 | 1.58e-03 | 201 |
| GO:000268316 | Esophagus | ESCC | negative regulation of immune system process | 231/8552 | 434/18723 | 8.48e-04 | 4.36e-03 | 231 |
| GO:0045637111 | Esophagus | ESCC | regulation of myeloid cell differentiation | 118/8552 | 210/18723 | 1.35e-03 | 6.43e-03 | 118 |
| GO:190210510 | Esophagus | ESCC | regulation of leukocyte differentiation | 152/8552 | 279/18723 | 1.82e-03 | 8.35e-03 | 152 |
| GO:00458381 | Esophagus | ESCC | positive regulation of membrane potential | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
| GO:000276115 | Esophagus | ESCC | regulation of myeloid leukocyte differentiation | 69/8552 | 120/18723 | 6.00e-03 | 2.21e-02 | 69 |
| GO:00332331 | Esophagus | ESCC | regulation of protein sumoylation | 18/8552 | 25/18723 | 7.04e-03 | 2.56e-02 | 18 |
| GO:0033235 | Esophagus | ESCC | positive regulation of protein sumoylation | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
| GO:00303165 | Esophagus | ESCC | osteoclast differentiation | 54/8552 | 94/18723 | 1.43e-02 | 4.65e-02 | 54 |
| GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
| hsa04120110 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
| hsa0412025 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
| hsa0412035 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIAS3 | SNV | Missense_Mutation | novel | c.690N>C | p.Lys230Asn | p.K230N | Q9Y6X2 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| PIAS3 | deletion | In_Frame_Del | novel | c.1709_1723delNNNNNNNNNNNNNNN | p.Leu570_Ala574del | p.L570_A574del | Q9Y6X2 | protein_coding | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR | ||
| PIAS3 | SNV | Missense_Mutation | novel | c.349C>A | p.Pro117Thr | p.P117T | Q9Y6X2 | protein_coding | tolerated(0.12) | benign(0.108) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PIAS3 | SNV | Missense_Mutation | novel | c.170T>C | p.Ile57Thr | p.I57T | Q9Y6X2 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PIAS3 | SNV | Missense_Mutation | c.1378N>A | p.Asp460Asn | p.D460N | Q9Y6X2 | protein_coding | tolerated(0.07) | probably_damaging(0.984) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| PIAS3 | SNV | Missense_Mutation | c.1378N>A | p.Asp460Asn | p.D460N | Q9Y6X2 | protein_coding | tolerated(0.07) | probably_damaging(0.984) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PIAS3 | SNV | Missense_Mutation | rs782639620 | c.305C>T | p.Ala102Val | p.A102V | Q9Y6X2 | protein_coding | tolerated(0.5) | benign(0) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PIAS3 | SNV | Missense_Mutation | c.427C>T | p.Arg143Trp | p.R143W | Q9Y6X2 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PIAS3 | SNV | Missense_Mutation | novel | c.947N>C | p.Val316Ala | p.V316A | Q9Y6X2 | protein_coding | deleterious(0) | benign(0.108) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
| PIAS3 | SNV | Missense_Mutation | novel | c.946N>A | p.Val316Met | p.V316M | Q9Y6X2 | protein_coding | deleterious(0) | possibly_damaging(0.467) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |